MAPT and Alzheimer disease: Up to now, the diagnosis of AD primarily relies on the quantitative assessment of Aβ and tau protein levels in the CSF, or the utilization of neuroimaging modalities such as amyloid and tau protein positron emission tomography (PET), both of which are medically invasive and costly [45, 46].